Harmony Biosciences Holdings, Inc. is a pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. WAKIX was developed for the treatment of excessive daytime sleepiness (EDS) in pediatric patients, six years and older, with narcolepsy. HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist. ZYN002 is an investigational drug product in development for the potential treatment of behavioral symptoms associated with Fragile X syndrome (FXS) and 22q11.2 deletion syndrome (22q). It also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 49.21% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 868.45M.
Overvalued
The company’s latest PE is 14.25, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 60.37M shares, increasing 3.16% quarter-over-quarter.
Held by John Hussman
Star Investor John Hussman holds 76.40K shares of this stock.